Screener
Gyre Therapeutics, Inc. GYRE Gyre — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Operating expenses: | |||
| Cost of revenues | 1,151 | — | 1,151 |
| Selling and marketing | 15,195 | — | 15,195 |
| Research and development | 3,337 | 5,014 | 8,351 |
| General and administrative | 2,858 | 4,417 | 7,275 |
| Total segment operating expenses | 22,541 | 9,431 | 31,972 |
| Income (loss) from segment operations | 4,230 | (6,468) | (2,238) |
| Other segment (loss) income, net: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre — research and development expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — research and development expense of $4.6M in Q2 2026.
- What does gyre — research and development expense mean?
- This metric represents the total costs incurred by the business segment for research, clinical trials, and development activities related to its drug pipeline. It reflects the company's investment in innovation and the advancement of therapeutic candidates through regulatory approval stages. Monitoring this expense helps investors assess the company's commitment to long-term growth and the intensity of its clinical development efforts.
Ask your AI about Gyre Therapeutics, Inc.'s gyre — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude